Enzon Pharmaceuticals Files Q2 2024 10-Q Report
Ticker: ENZN · Form: 10-Q · Filed: Aug 8, 2024 · CIK: 727510
| Field | Detail |
|---|---|
| Company | Enzon Pharmaceuticals, INC. (ENZN) |
| Form Type | 10-Q |
| Filed Date | Aug 8, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Enzon Pharma dropped its Q2 10-Q. Check financials.
AI Summary
Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the second quarter of 2024. Key financial data and disclosures relevant to investors are presented in this report.
Why It Matters
This 10-Q filing provides crucial financial and operational insights into Enzon Pharmaceuticals' performance during the second quarter of 2024, impacting investor decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Enzon faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in its SEC filings.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20240808 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- 20240808 (date) — Date of filing
- CRANFORD, NJ (location) — Company's business and mailing address
FAQ
What is the primary business of Enzon Pharmaceuticals, Inc.?
Enzon Pharmaceuticals, Inc. is primarily involved in the biological products sector, specifically excluding diagnostic substances, as indicated by its Standard Industrial Classification code [2836].
What is the fiscal year end for Enzon Pharmaceuticals?
Enzon Pharmaceuticals' fiscal year ends on December 31st.
Where is Enzon Pharmaceuticals, Inc. located?
The company's business and mailing address is 20 Commerce Drive, Suite 135, Cranford, NJ 07016.
What type of stock is mentioned in relation to Enzon Pharmaceuticals?
The filing mentions 'us-gaap:SeriesCPreferredStockMember' and 'us-gaap:PreferredStockMember' in relation to Enzon Pharmaceuticals.
What is the SEC file number for Enzon Pharmaceuticals?
The SEC file number for Enzon Pharmaceuticals is 000-12957.
Filing Stats: 4,698 words · 19 min read · ~16 pages · Grade level 14.3 · Accepted 2024-08-08 16:06:02
Filing Documents
- enzn-20240630x10q.htm (10-Q) — 721KB
- enzn-20240630xex31d1.htm (EX-31.1) — 13KB
- enzn-20240630xex32d1.htm (EX-32.1) — 6KB
- 0001410578-24-001220.txt ( ) — 3167KB
- enzn-20240630.xsd (EX-101.SCH) — 31KB
- enzn-20240630_cal.xml (EX-101.CAL) — 19KB
- enzn-20240630_def.xml (EX-101.DEF) — 96KB
- enzn-20240630_lab.xml (EX-101.LAB) — 219KB
- enzn-20240630_pre.xml (EX-101.PRE) — 169KB
- enzn-20240630x10q_htm.xml (XML) — 320KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION 3 Item 1.
Financial Statements
Financial Statements 3 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 18 Item 4.
Controls and Procedures
Controls and Procedures 19
– OTHER INFORMATION
PART II – OTHER INFORMATION 19 Item 1.
Legal Proceedings
Legal Proceedings 19 Item 1A.
Risk Factors
Risk Factors 19 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 20
Signatures
Signatures 21 2 Table of Contents
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) June 30, December 31, 2024 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 46,229 $ 47,012 Other current assets 409 331 Total current assets 46,638 47,343 Deferred tax asset 356 359 Total assets $ 46,994 $ 47,702 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 331 $ 331 Accrued expenses and other current liabilities 79 108 Dividends payable on Series C preferred stock — 1,275 Total current liabilities 410 1,714 Commitments and contingencies Mezzanine equity: Series C preferred stock - $ 0.01 par value, 40,000 shares authorized, issued and outstanding (liquidation value $ 1,089 and $ 1,062 per share) at June 30, 2024 and December 31, 2023 43,545 42,483 Stockholders' equity: Preferred stock - $ 0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock - $ 0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at June 30, 2024 and December 31, 2023 742 742 Additional paid-in capital 72,371 73,433 Accumulated deficit ( 70,074 ) ( 70,670 ) Total stockholders' equity 3,039 3,505 Total liabilities, mezzanine equity and stockholders' equity $ 46,994 $ 47,702 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents ENZON PHARMACEUTICALS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) Three months ended Six months ended June 30, June 30, 2024 2023 2024 2023 Revenues: License fees $ 26 $ — $ 26 $ — Total revenues 26 — 26 — Operating expenses: General and administrative 351